STOCK TITAN

Enanta Pharmaceuticals Inc - ENTA STOCK NEWS

Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.

Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.

Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.

Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.

Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.

Rhea-AI Summary
Enanta Pharmaceuticals, Inc. reported financial results for its fiscal first quarter ended December 31, 2023, with total revenue of $18.0 million. The company aims to announce topline data for RSVPEDs and EDP-323 challenge study in Q3 2024. They also expanded into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria, targeting a development candidate selection in 2024. Cash and Marketable Securities totaled $337.2 million at December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that its President and CEO, Jay R. Luly, Ph.D., and Chief Product Strategy Officer, Tara L. Kieffer, Ph.D., will participate in a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The event will be live webcast and accessible on the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
conferences
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) plans to report its fiscal first-quarter financial results on February 7, 2024, after the U.S. market closes. The company will host a conference call to discuss the results and provide an update on its business and research and development pipeline. A live webcast of the event will be accessible on Enanta's website. Participants can also join by phone and a replay of the webcast will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
conferences earnings
Rhea-AI Summary
Enanta Pharmaceuticals, a clinical-stage biotechnology company (NASDAQ:ENTA), announced expansion into immunology with a new discovery program of oral KIT inhibitors for Chronic Spontaneous Urticaria (CSU). They also expect topline data from at least one Phase 2 study of Zelicapavir (EDP-938), an N-Protein Inhibitor in development to treat Respiratory Syncytial Virus (RSV), in 3Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.8%
Tags
none
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
conferences
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (ENTA) announced that its President and CEO, Dr. Jay R. Luly, will participate in a fireside chat at Evercore ISI HealthCONx Conference on November 29, 2023. The event will be live webcasted and accessible through the company's website. A replay will also be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
conferences
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV). The company expects to report data in Q3 2024. Enanta also streamlined business and significantly lowered 2024 R&D and G&A spending guidance to support ongoing operations. Cash and Marketable Securities totaled $370 million at September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.52%
Tags
-
Rhea-AI Summary
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) to Report Q4 and Full Year 2023 Financial Results and Host Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Enanta Pharmaceuticals Inc

Nasdaq:ENTA

ENTA Rankings

ENTA Stock Data

108.80M
19.90M
6.58%
96.11%
12.18%
Biotechnology
Pharmaceutical Preparations
Link
United States
WATERTOWN